Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics
Journal of Enzyme Inhibition and Medicinal Chemistry · 31.12.2025 · 40 (1)
DOI: 10.1080/14756366.2025.2489720 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, online erschienen am 21.04.2025. Verfasst von Ram Sharma und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, Protein Kinase Inhibitors, Neoplasms, DNA-Activated Protein Kinase. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 344 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council of Taiwan.
Abstract (Originalsprache)
This review discusses the critical roles of Ataxia Telangiectasia Mutated Kinase (ATM), ATM and Rad3-related Kinase (ATR), and DNA-dependent protein kinase (DNA-PK) in the DNA damage response (DDR) and their implications in cancer. Emphasis is placed on the intricate interplay between these kinases, highlighting their collaborative and distinct roles in maintaining genomic integrity and promoting tumour development under dysregulated conditions. Furthermore, the review covers ongoing clinical trials, patent literature, and medicinal chemistry campaigns on ATM/ATR/DNA-PK inhibitors as antitumor agents. Notably, the medicinal chemistry campaigns employed robust drug design strategies and aimed at assembling new structural templates with amplified DDR kinase inhibitory ability, as well as outwitting the pharmacokinetic liabilities of the existing DDR kinase inhibitors. Given the success attained through such endeavours, the clinical pipeline of DNA repair kinase inhibitors is anticipated to be supplemented by a reasonable number of tractable entries (DDR kinase inhibitors) soon.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
- Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.
- Molecular Medicine, University of South Florida, Tampa, FL, USA.
- Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Förderung
- National Science and Technology Council of Taiwan
Zitieren
APA
Sharma, R., Mishra, A., Bhardwaj, M., Singh, G., Indira Harahap, L. V., Vanjani, S., Pan, C. H., & Nepali, K. (2025). Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics. Journal of Enzyme Inhibition and Medicinal Chemistry, 40(1). https://doi.org/10.1080/14756366.2025.2489720
Vancouver
Sharma R, Mishra A, Bhardwaj M, Singh G, Indira Harahap LV, Vanjani S, et al. Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics. Journal of Enzyme Inhibition and Medicinal Chemistry. 2025;40(1). doi:10.1080/14756366.2025.2489720
BibTeX
@article{Sharma2025,
author = {Sharma, Ram and Mishra, Anshul and Bhardwaj, Monika and Singh, Gurpreet and Indira Harahap, Larasati Vanya and Vanjani, Sakshi and Pan, Chun Hsu and Nepali, Kunal},
title = {Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2025},
volume = {40},
number = {1},
doi = {10.1080/14756366.2025.2489720}
}
EUVIMED